Underdog Pharmaceuticals

Underdog Pharmaceuticals, now known as Cyclarity, was founded with the mission to develop interventions targeting toxic forms of cholesterol to treat age-related diseases. The company's core vision is to provide true disease-modifying treatments that address the underlying causes of conditions like atherosclerosis, heart attacks, and strokes. Their primary product focuses on removing arterial plaque by clearing non-degradable cholesterol that accumulates within arterial walls, aiming to offer a simple and affordable preventive therapy for widespread use.

Notable figures affiliated with Cyclarity include experts in pharmaceutical innovation and age-related disease research. The company has garnered attention from key investors in the biotech sector, reflecting confidence in their groundbreaking approach. Cyclarity's significant achievements include advancing their drug development pipeline and demonstrating potential in preclinical studies. Their impact lies in the promise of transforming the treatment landscape for common age-related conditions, potentially improving the quality of life for millions worldwide.